Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“The last several months have marked a period of tremendous advancement for our leading gene therapy programs”

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“With U.S. Food & Drug Administration (FDA) alignment on a potential pivotal endpoint and Cohort 2 over-enrolled with 11 participants, we expect to have data in Q1 2027, followed by dosing in a potential pivotal Phase 3 trial anticipated to begin in the second half of 2027.”

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“For OPGx-LCA5, we have fully enrolled our registrational Phase 3 trial and expect to begin dosing participants this quarter. We are also advancing our third gene therapy program into the clinic following IND clearance for OPGx-RDH12.”

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams.”

George Magrath, M.D. and Chief Executive Officer of Opus Genetics

“With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases”